Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug

By /

Yuviwel will compete with BioMarin’s Voxzogo. Meanwhile, BridgeBio is working to bring its own achondroplasia drug, the FGFR3 blocker infigratinib, to the market.

Scroll to Top